Does executive impairment define a frontal variant of Alzheimer's disease?
Michael Woodward, Henry Brodaty, Karyn Boundy, David Ames, Greg Blanch, Robert Balshaw
International Psychogeriatrics | CAMBRIDGE UNIV PRESS | Published : 2010
The first four authors have all been members of advisory boards funded by the companies marketing galantamine, donepezil and rivastigmine. They have been members of the PRIME database Scientific Advisory Committee (SAC), funded by Janssen-Cilag Pty Ltd Australia, and were funded for this activity. Greg Blanch is an employee of Janssen-Cilag Pty Ltd Australia and Robert Balshaw is an employee of Syreon Corporation, Canada, which processed the data and was paid by Janssen-Cilag Pty Ltd Australia to do this.